Eledon Pharmaceuticals
ELDN
15 hedge funds and large institutions have $15M invested in Eledon Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 5 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
0.03% less ownership
Funds ownership: 2.34% → 2.31% (-0.03%)
7% less capital invested
Capital invested by funds: $16.1M → $15M (-$1.11M)
21% less funds holding
Funds holding: 19 → 15 (-4)
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LSC
Lyon Street Capital
Sausalito,
California
|
+$585K |
| 2 |
Renaissance Technologies
New York
|
+$97.3K |
| 3 |
Millennium Management
New York
|
+$46.8K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$22.2K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$14.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECM
Element Capital Management
New York
|
-$145K |
| 2 |
Goldman Sachs
New York
|
-$76K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$13.6K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$3K |
| 5 |
BlackRock
New York
|
-$2.49K |
ELDN Hedge Fund Activity: Q3 2017 in Review
15 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Eledon Pharmaceuticals (ELDN) for Q3 2017, worth a combined $15M — down 6.9% from $16.1M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of ELDN and 1 opened new positions — a net loss of 4 holders — while 3 trimmed existing stakes and 5 added.
The largest buyer was Lyon Street Capital, adding an estimated $585K. The largest seller was Element Capital Management, exiting entirely with an estimated $145K sold.
- 15 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q3 2017, down from 19 in Q2 2017.
- Funds reported $15M of Eledon Pharmaceuticals stock for Q3 2017, down 6.9% quarter-over-quarter.
- 1 fund opened new Eledon Pharmaceuticals positions in Q3 2017 and 5 closed out, a net change of -4 holders.
- The largest Eledon Pharmaceuticals buyer in Q3 2017 was Lyon Street Capital, an estimated $585K added.
- The largest Eledon Pharmaceuticals seller in Q3 2017 was Element Capital Management, an estimated $145K sold.
Based on aggregated 13F filings for Q3 2017.